CAR-T Cell Therapy in Gurgaon & Faridabad
Next-generation living-cell immunotherapy transforming treatment for refractory & relapsed blood cancers. Reprogramming your own immune cells into targeted cancer-destroying defenders.
Targeted
CD19 & BCMA Precision Antigens
Living Drug
Multiplies Inside The Body
24×7 ICU
Specialized CRS & ICANS Protocol
India Made
Global Standard Accessible Regimens
How CAR-T Cell Therapy Works
A breakthrough modality replacing repetitive chemotherapy cycles with a single targeted cellular infusion.
Reprogrammed Autologous T-Cells
Patient’s white blood cells (T-lymphocytes) are collected via non-invasive apheresis and genetically modified using a harmless viral vector to express Chimeric Antigen Receptors (CAR).
Targeted Cancer Eradication
The engineered CAR proteins act as precision GPS devices that hunt down and lock onto specific cancer surface markers (like CD19 or BCMA) while leaving healthy vital tissues unharmed.
Long-Term Cellular Surveillance
Once infused, CAR-T cells proliferate into millions of active defenders and form immune memory cells that remain in circulation for months or years to prevent tumor relapse.
Cancers Treated With CAR-T Across Delhi NCR
Indicated for patients who have relapsed or shown resistance to conventional chemotherapy and stem cell transplants.
B-Cell Leukemias & Aggressive Lymphomas
- B-Cell Acute Lymphoblastic Leukemia (B-ALL): Relapsed or refractory pediatric and young adult B-ALL showing sustained molecular remission.
- Diffuse Large B-Cell Lymphoma (DLBCL): Frontline cellular cure for aggressive non-Hodgkin lymphoma relapsed post-chemotherapy.
- High-Grade B-Cell Lymphoma: Targeted CD19-directed T-cell therapy for refractory double/triple-hit lymphomas.
- Transformed Follicular Lymphoma: For indolent lymphomas transformed into aggressive systemic disease.
Relapsed Lymphomas & Plasma Cell Disorders
- Multiple Myeloma (BCMA-Targeted): Breakthrough cellular therapy for triple-class exposed, relapsed, or refractory multiple myeloma.
- Mantle Cell Lymphoma (MCL): Overcoming BTK inhibitor resistance with autologous engineered CAR-T constructs.
- Follicular Lymphoma (FL): Refractory cases showing profound, durable response rates following CD19 re-infusion.
- Primary Mediastinal Large B-Cell Lymphoma: Specialized therapeutic pathways for salvage-resistant thoracic mass.
The CAR-T Cell Pathway At Marengo Asia Hospitals
A synchronized sequence coordinated between our cellular apheresis unit, genetic laboratory, and critical care suites.
Patient Evaluation
Organ assessment, flow cytometry, and confirmation of CD19/BCMA antigen expression.
T-Cell Apheresis
Painless blood collection via specialized cell separator machine to harvest healthy T-cells.
Lab Engineering
Cells are modified with CAR receptors and multiplied to target doses under sterile GMP standards.
Conditioning & Infusion
Short lymphodepleting prep followed by intravenous CAR-T cell infusion (Day 0).
ICU Monitoring
7–14 days of specialized clinical observation to manage immune activation and engraftment.
Specialized CRS & ICANS Critical Care Protocol
CAR-T therapy can induce Cytokine Release Syndrome (CRS) and transient neurotoxicity (ICANS) as engineered cells vigorously attack tumors. At Marengo Asia Hospitals (Gurugram & Faridabad), our board-certified intensivist and transplant teams maintain 24×7 ICU protocols with immediate availability of Tocilizumab, steroids, and advanced neurological monitoring.
Frequently Asked Questions on CAR-T Therapy
How is CAR-T Cell Therapy different from a traditional Bone Marrow Transplant?
In a Bone Marrow Transplant (BMT), healthy blood-forming stem cells are transplanted to replace destroyed bone marrow. In CAR-T therapy, mature immune T-cells are collected, genetically re-engineered in a laboratory to specifically detect cancer cells, and re-infused. It does not require a donor match and serves as a targeted living immunotherapy.
What financial support & special treatment access is available for CAR-T?
CAR-T cell therapy is an advanced medical treatment. To help patients access this therapy without delays, Marengo Asia Hospitals provides:
• Patient Funding Support: Dedicated guidance for health insurance pre-authorizations, specialized oncology grants, and medical crowdfunding platforms.
• Compassionate Access & Co-Pay Initiatives: Working closely with indigenous therapy developers (such as NexCAR19) to optimize pricing accessibility.
• Clinical Trial Access: Opportunities for eligible refractory patients to participate in authorized cellular therapy trials.
How long does the complete CAR-T procedure and hospital stay take?
Following T-cell harvesting (apheresis), cell reprogramming in the laboratory takes approximately 2 to 3 weeks. During this period, the patient can often remain at home. After the infusion, hospital observation typically lasts 10 to 14 days in our dedicated BMT/hematology unit to ensure safe monitoring of initial immune response and cell proliferation.
Is CAR-T Cell Therapy Right For Your Diagnosis?
Connect directly with our Lead Hematologists and Cellular Therapy Specialists at Marengo Asia Hospitals, Gurugram & Faridabad for a comprehensive eligibility review.
